Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Files SC Immunoglobulin for Immune Disorders in Japan
October 27, 2022
- Sanofi Seeks Dupixent’s Pediatric Dosage for Eczema in Japan
October 27, 2022
- Astellas Bags Option Rights to 2 Taysha Gene Therapy Programs
October 26, 2022
- Toho Picked as Single Wholesaler for LEO Pharma’s Dovonex
October 26, 2022
- Daiichi Sankyo’s FLT3 Inhibitor Gets FDA’s Priority Review for 1st Line AML
October 26, 2022
- Chugai Logs Bumper Earnings in January-September on New Products, Exports to Roche
October 25, 2022
- Bayer Launches Xarelto Tablets 2.5 mg for PAD as Single-Channel Product
October 25, 2022
- LEO Pharma to Take Over Dovonex Distribution, Set Up Solo Sales Regime in Japan
October 25, 2022
- GSK Seeks Japan Approval of RSV Vaccine
October 24, 2022
- Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
- Approval by January Unlikely for SanBio’s Lead Cell Therapy as Production Review Stalls
October 21, 2022
- Sunovion to Divest US Market Rights of 2 Drugs to Lupin for US$75 Million
October 21, 2022
- Kyowa Kirin Assigns Bone Metabolism Specialists to Promote Crysvita in Japan
October 20, 2022
- Bayer to Halt Sale of PAH Med Ventavis in Japan over Nebulizer Supply Issue
October 20, 2022
- MSD Started Work to Develop Easier-to-Swallow Form of Lagevrio: Exec
October 20, 2022
- Sumitomo Aiming to Take the Lead in Developing Universal Flu Vaccines
October 19, 2022
- Chugai’s Integrated Drug Discovery Research Center Completed in Yokohama
October 19, 2022
- Kyowa Kirin Files Intas-Licensed Mitomycin for Cancer Use in Japan
October 19, 2022
- Bayer to Distribute Xarelto Tablets 2.5 mg via Single Wholesaler
October 18, 2022
- Fuji Pharma Files 1st Biosimilar Out of Alvotech Collaboration
October 18, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…